Biotest Aktiengesellschaft (ETR:BIO - Get Free Report) was down 1.4% during trading on Tuesday . The company traded as low as €40.60 ($41.86) and last traded at €40.80 ($42.06). Approximately 121 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 1,927 shares. The stock had previously closed at €41.40 ($42.68).
Biotest Aktiengesellschaft Stock Performance
The firm has a 50-day simple moving average of €41.43 and a two-hundred day simple moving average of €41.61. The company has a current ratio of 2.45, a quick ratio of 1.66 and a debt-to-equity ratio of 116.50. The company has a market capitalization of $807.43 million, a price-to-earnings ratio of 9.83 and a beta of 0.24.
About Biotest Aktiengesellschaft
(
Get Free Report)
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Recommended Stories
Before you consider Biotest Aktiengesellschaft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biotest Aktiengesellschaft wasn't on the list.
While Biotest Aktiengesellschaft currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
